On Sunday, BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) reached a binding settlement with Ascendis Pharma A/S (NASDAQ:ASND)to resolve all global patent disputes regarding the medication Yuviwel.
Ascendis Pharma’s Yuviwel (navepegritide, developed as TransCon CNP) is a once-weekly prescription injection approved by the FDA to increase linear height growth in children aged 2 years and older with achondroplasia who have open growth plates.
In March, the FDA approved Yuviwel, the first and only once-weekly treatment for children with achondroplasia.
Ends Global Legal Disputes
The sweeping agreement ends ongoing legal conflicts and intellectual property challenges between the two pharmaceutical companies, including a U.S. International Trade Commission (ITC) investigation.
